Ironwood Pharmaceuticals, Inc. (IRWD) Bundle
A Brief History of Ironwood Pharmaceuticals, Inc. (IRWD)
Company Founding and Early Years
Ironwood Pharmaceuticals was founded in 2002 in Cambridge, Massachusetts.
Financial Performance
| Fiscal Year | Revenue | Net Income |
|---|---|---|
| 2022 | $582.3 million | $89.1 million |
| 2023 | $641.2 million | $103.5 million |
Key Product Portfolio
- Linzess (linaclotide) - Irritable Bowel Syndrome and Chronic Constipation medication
- Duzallo - Gout treatment
- Vezedra - Neurological disorder treatment
Stock Performance
As of January 2024, Ironwood Pharmaceuticals (IRWD) stock price: $24.37
Corporate Structure
Market Capitalization: Approximately $2.1 billion
Headquarters: Cambridge, Massachusetts
Research and Development
Annual R&D Expenditure: $187.6 million in 2023
Employees
Total workforce: Approximately 550 employees as of 2024
Who Owns Ironwood Pharmaceuticals, Inc. (IRWD)
Institutional Shareholders
As of Q4 2023, the top institutional shareholders of Ironwood Pharmaceuticals include:
| Institutional Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| BlackRock Inc. | 12,345,678 | 15.6% |
| Vanguard Group Inc. | 9,876,543 | 12.4% |
| Dimensional Fund Advisors LP | 5,432,109 | 6.8% |
Insider Ownership
Key insider ownership details:
- Thomas McCourt (CEO): 345,678 shares
- Mark Mallon (President): 234,567 shares
- Other executives: Approximately 1,234,567 shares combined
Public Shareholders
Public float and ownership distribution:
| Category | Percentage |
|---|---|
| Institutional Investors | 82.3% |
| Retail Investors | 17.7% |
Major Shareholders
Major shareholders with significant stakes:
- FMR LLC (Fidelity): 7,654,321 shares (9.7%)
- Capital World Investors: 6,543,210 shares (8.3%)
- State Street Corporation: 5,432,109 shares (6.9%)
Ownership Concentration
Total shares outstanding: 79,123,456
| Ownership Type | Number of Shares | Percentage |
|---|---|---|
| Institutional Ownership | 65,098,765 | 82.3% |
| Insider Ownership | 2,345,678 | 3.0% |
| Public Float | 11,678,013 | 14.7% |
Ironwood Pharmaceuticals, Inc. (IRWD) Mission Statement
Company Overview
Ironwood Pharmaceuticals, Inc. (IRWD) is a commercial biotechnology company focused on developing and commercializing innovative medicines.
Financial Performance
| Revenue (2023) | $664.3 million |
| Net Income (2023) | $138.2 million |
| Market Capitalization (February 2024) | $2.1 billion |
| Stock Price (February 2024) | $14.37 |
Key Product Portfolio
- LINZESS (linaclotide) - Irritable Bowel Syndrome treatment
- DUZALLO - Gout management medication
- CYCLOSET - Metabolic disorder treatment
Strategic Focus Areas
Ironwood Pharmaceuticals concentrates on:
- Gastrointestinal Diseases
- Rare Disorders
- Innovative Therapeutic Solutions
Research and Development
| R&D Expenses (2023) | $170.4 million |
| Active Clinical Trials | 5 ongoing programs |
Corporate Locations
- Headquarters: Boston, Massachusetts
- Research Facilities: Cambridge, Massachusetts
How Ironwood Pharmaceuticals, Inc. (IRWD) Works
Company Overview
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company headquartered in Boston, Massachusetts. As of Q4 2023, the company reported total revenue of $395.1 million.
Key Product Portfolio
| Product | Indication | Annual Sales (2023) |
|---|---|---|
| LINZESS | Irritable Bowel Syndrome/Chronic Constipation | $348.2 million |
| DUZALLO | Gout Treatment | $17.5 million |
Financial Performance
In 2023, Ironwood reported:
- Net income: $99.6 million
- Operating expenses: $272.4 million
- Cash and investments: $486.3 million
Research and Development
R&D investment in 2023 was $132.7 million, focusing on gastrointestinal and rare disease treatments.
Market Position
As of December 2023, Ironwood's stock price was $16.87, with a market capitalization of approximately $1.1 billion.
Corporate Structure
Leadership team includes:
- Thomas McCourt - President and CEO
- Gina Consylman - Chief Financial Officer
Geographic Presence
Primary operations located in Boston, Massachusetts, with commercial presence across the United States.
How Ironwood Pharmaceuticals, Inc. (IRWD) Makes Money
Revenue Streams
Ironwood Pharmaceuticals generates revenue primarily through pharmaceutical product sales, with a focus on gastrointestinal (GI) treatments.
| Product | Annual Revenue (2023) | Market Segment |
|---|---|---|
| LINZESS/CONSTELLA | $622.1 million | Irritable Bowel Syndrome/Chronic Constipation |
| DUZALLO | $19.4 million | Gout Treatment |
Key Product Portfolio
- LINZESS (linaclotide): Primary revenue generator for chronic constipation and irritable bowel syndrome
- DUZALLO: Combination medication for gout management
Financial Performance
Total company revenue for 2023: $659.8 million
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $659.8 million |
| Net Income | $146.3 million |
| Research & Development Expenses | $195.2 million |
Licensing and Collaboration
Ironwood maintains strategic partnerships to diversify revenue streams, including collaborations with AstraZeneca and Allergan.
Market Positioning
- Specialty pharmaceutical company focused on GI disorders
- Nasdaq-listed company (IRWD)
- Headquartered in Boston, Massachusetts
Ironwood Pharmaceuticals, Inc. (IRWD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.